BioCentury
ARTICLE | Distillery Therapeutics

Neurology

February 15, 2017 6:03 PM UTC

Studies in mice suggest inhibiting HDAC2 could help treat peripheral nerve damage. In a mouse model of sciatic nerve injury, Schwann cell-specific knockout of HDAC2 increased axonal regrowth and sprouting compared with normal HDAC2 expression. Also in the model, the HDAC2 inhibitor mocetinostat increased motor and sensory function recovery compared with vehicle. Next steps could include testing HDAC2 inhibition in other models of peripheral nerve damage.

Mirati Therapeutics Inc. and Taiho Pharmaceutical Co. Ltd. have mocetinostat (MGCD0103; MG-0103), an HDAC1/HDAC2 inhibitor, in Phase II testing for B cell lymphoma, bladder cancer, myelodysplastic syndrome (MDS) and non-Hodgkin’s lymphoma (NHL) and preclinical testing for non-small cell lung cancer (NSCLC)...

BCIQ Target Profiles

HDAC2